Tom Goodrich

Tom Goodrich co-founded Corner Ventures in 2018 and is a General Partner of the firm, leading Corner’s biotech investments.

Tom is responsible for investments in Armo Biosciences (Acquired by Lilly), Atara Biotherapeutics (NASDAQ:ATRA) and Arresto Biosciences (Acquired by Gilead), Dantari Pharmaceuticals, Latigo Biotherapeutics, and Oncovalent Therapeutics.

Prior to Corner, Tom was Co-Founder and Managing Director of DAG Ventures, a mid-stage venture capital partnership working with entrepreneurs and select early-stage VCs, and before that was a Co-Founder and Managing Director of private equity firm Duff Ackerman and Goodrich.

Tom received his MBA from Stanford GSB and a bachelor’s degree from Dartmouth College.